Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Esophageal Neoplasms 2Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1

Interventions

pembrolizumab 38Bevacizumab 23Cyclophosphamide 22Standard of Care 18Blood Specimen Collection 17Carboplatin 16Paclitaxel 15Nivolumab 14Gemcitabine 14Pemetrexed 13Exercise 13Cisplatin 12atezolizumab 11Radiotherapy 11Fluorouracil 11Doxorubicin 11Surveys and Questionnaires 9Rituximab 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Cetuximab 9Biopsy 9130-nm albumin-bound paclitaxel 9durvalumab 8abemaciclib 8Docetaxel 8olaparib 7Temozolomide 7Prednisone 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × TP protocol × 90 days × Clear all
NCT06532539 2026-04-24

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
30 enrolled
Gynecologic

Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡